Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| G-1 Impurities | G-1 Impurities are integral in pharmaceutical research, playing a crucial role in the synthesis of selective estrogen receptor modulators (SERMs). These impurity profiles assist in developing therapies targeting breast cancer and osteoporosis, ensuring the efficacy and safety of novel drug formulations by identifying and minimizing potential adverse reactions. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| GLPG-1690 | GLPG-1690, an imidazopyridine derivative, has been found to be a selective autotaxin inhibitor that could probably be effective as an anti-inflammatory agent and is under Phase II trial against Idiopathic pulmonary fibrosis (IPF). Group: Pharmaceutical. CAS No. 1628260-79-6. Pack Sizes: 200 mg. Product ID: B0084-475919. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| (1R)-1β-Ethenyl-2α-(β-D-glucopyranosyloxy)-1, 2, 7, 8, 13, 13bα, 14, 14aα-octahydro-5H-indolo[2, 3-a]pyrano[3, 4-g]quinolizine-5-one | Vincosamide isolated from the herbs of Vincoside lactam. It can mediate DNA strand. Group: Pharmaceutical. CAS No. 23141-27-7. Pack Sizes: 1 mg. Product ID: NP0313. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 5H-Benzo(g)-1,3-benzodioxolo(6,5,4-de)quinoline, 6,7-dihydro-9,10-dime thoxy-7-methyl- | Dehydrocrebanine comes from the herbs of Stephania yunnanensis. And Dehydrocrebanine has strong activity against promyelocytic leukemia cells (HL-60) , and crebanine shows weak activity against cancer cell lines; both of them show cytotoxicity against MRC-5 cells. Group: Pharmaceutical. CAS No. 77784-22-6. Pack Sizes: 1 mg. Product ID: NP0494. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Albiglutide | Albiglutide is a glucagon-like peptide-1 (GLP-1) agonist approved for the treatment of type 2 diabetes. Uses: Incretins; antidiabetic. Group: Pharmaceutical. CAS No. 782500-75-8. Pack Sizes: 10 mg. Product ID: BAT-016102. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Cotadutide | Cotadutide (MEDI 0382) is a subcutaneous GLP-1 and glucagon receptor dual agonist that can be used to treat type 2 diabetes. Group: Pharmaceutical. CAS No. 1686108-82-6. Pack Sizes: 10 mg. Product ID: BAT-009970. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Ala(18)-Semaglutide | D-Ala(18)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449831. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Ala(19)-Semaglutide | D-Ala(19)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449832. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Ala(24)-Semaglutide | D-Ala(24)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449836. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Allo-Thr5-Semaglutide | D-Allo-Thr5-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449822. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Allo-Thr7-Semaglutide | D-Allo-Thr7-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449823. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Arg(28)-Semaglutide | D-Arg(28)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449840. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| [D-Arg30]-Semaglutide | [D-Arg30]-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449841. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Asp(9)-Semaglutide | D-Asp(9)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449824. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Glu(15)-Semaglutide | D-Glu(15)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449830. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Glu(21)-Semaglutide | D-Glu(21)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449834. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| [D-Glu3]-Semaglutide | [D-Glu3]-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449821. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-(+)-Glucono-1,5-lactone | 500g Pack Size. Group: Aroma Chemicals, Biochemicals, Flavours and Fragrance Materials. Formula: C6H10O6. CAS No. 90-80-2. Prepack ID : 27771364-500g. Molecular Weight : 178.14. |  |
| D-His(1)-Semaglutide | D-[His]-1-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-425567. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Leu(14)-Semaglutide | D-Leu(14)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449829. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Lys(20)-Semaglutide | D-Lys(20)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449833. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Phe(22)-Semaglutide | D-Phe(22)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449835. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Ser(11)-Semaglutide | D-Ser(11)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-087489. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Ser(12)-Semaglutide | D-Ser(12)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449827. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Ser(8)-Semaglutide | D-Ser(8)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-425538. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Trp(25)-Semaglutide | D-Trp(25)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449837. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Tyr(13)-Semaglutide | D-Tyr(13)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449828. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Val(10)-Semaglutide | D-Val(10)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449825. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-Val(27)-Semaglutide | D-Val(27)-Semaglutide is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449839. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Exenatide acetate | Exenatide acetate is a potent peptide agonist of the glucagon-like peptide 1 (GLP-1) receptor with Ki value of 136 pM. It is a 39 amino acid peptide, which increases intracellular cAMP in pancreatic acinar cells and has no effect on VIP receptors. It was first isolated from the venom of H. horridum and consequently synthesized. It stimulates proliferation of HCAECs through PKA-PI3K/Akt-eNOS activation pathways via a GLP-1 receptor-dependent mechanism. It also stimulates glucose-induced insulin secretion in isolated rat islets and proinsulin expression in mouse insulinoma βTC-1 cells. It protects hippocampal neurons against glutamate-induced apoptosis, suggesting utility in neurodegenerative diseases. It also has anxiolytic and anti-depressant effects and induces satiety. It is an incretin mimetic approved for type 2 diabetes mellitus treatment. It also has neurotrophic/protective activity in cellular and animal models of stroke, Alzheimer's and Parkinson's diseases. Group: Pharmaceutical. CAS No. 914454-01-6. Pack Sizes: 100 mg. Product ID: BAT-010771. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Exendin 3 (9-39) | Exendin (9-39) is a specific and competitive glucagon-like peptide-1receptor antagonist (Kd = 1.7 nM at cloned human GLP-1 receptors). Exendin (9-39) inhibits insulin release and cAMP production caused by GLP-1 (7-36), exendin-3, and exendin-4. Group: Pharmaceutical. CAS No. 133514-43-9. Pack Sizes: 1 mg. Product ID: BAT-006203. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ezatiostat | Ezatiostat is a glutathione analog that acts as an inhibitor of glutathione S-transferase (GST) P1-1. TLK117, the active form of ezatiostat, inhibits GSTP1-1, resulting in phosphorylation of JNK, restoring JNK-mediated cellular proliferation and differentiation signaling pathways. Group: Pharmaceutical. CAS No. 168682-53-9. Pack Sizes: 25 mg. Product ID: BAT-010079. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| FILTER CIRCLES GF-1 | FILTER CIRCLES GF-1, Suppliers of laboratory chemicals wanted in the United Kingdom |  |
| Fmoc-His-Aib-OH TFA | An intermediate in the synthesis of Semaglutide, an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. Group: Pharmaceutical. CAS No. 1446013-08-6. Pack Sizes: 100 mg. Product ID: B2692-383273. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH | Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH is a yellowish medical intermediate in the synthesis of Tirzepatide. Tirzepatide is a dual GIP and GLP-1 receptor agonist and a drug candidate for the treatment of type 2 diabetes. Group: Pharmaceutical. CAS No. 2460751-66-8. Pack Sizes: 1 g. Product ID: B1370-449764. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| GLP-1(7-36) amide | GLP-1(7-36) amide is a glucose-dependent insulinotropic peptide displaying high affinity for GLP-1 receptors expressed in rat insulinoma-derived RINm5F cells (Kd = 204 pM). GLP-1 (7-36) amide exhibits antiapoptotic effects in hippocampal neurons and reduces food intake in fasted rats following central administration. Group: Pharmaceutical. CAS No. 107444-51-9. Pack Sizes: 1 mg. Product ID: BAT-006200. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| GLP-1(7-37) | GLP-1 (7-37) is an insulinotropic peptide generated from the precursor peptide GLP-1 (1-37). It is a potent stimulator of insulin secretion at concentrations as low as 5 X 10(-11) M and has no effect on insulin secretion even at concentrations as high as 5 X 10(-7) M. It participates in the physiological regulation of insulin secretion. Uses: Glp-1 (7-37) acetate participates in the physiological regulation of insulin secretion. Group: Pharmaceutical. CAS No. 106612-94-6. Pack Sizes: 1 mg. Product ID: BAT-006116. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| GLP-1 TFA | GLP-1 is a potent insulin secretagogue that has multiple synergetic effects on the glucose-dependent insulin secretion pathways of the beta-cell. Group: Pharmaceutical. Pack Sizes: 25 mg. Product ID: BAT-016125. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| GLUCOSE-1-PHOSPHORIC ACID DISODIUM | GLUCOSE-1-PHOSPHORIC ACID DISODIUM, Suppliers of laboratory chemicals wanted in the United Kingdom | |
| GlyH-101 | N-2-Naphthalenyl-glycine 2-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene]hydrazide is a glycine hydrazide that has recently been shown to block CFTR channels. However, its effects on cardiomyocytes are unknown. Studies have demonstrated that GlyH-101 blocks cardiac I Cl.PKA channels in a similar fashion to that reported for recombinant CFTR. Group: Pharmaceutical. CAS No. 328541-79-3. Pack Sizes: 25 mg. Product ID: B0084-430555. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| GSK 189254A | GSK-189,254 is a H3 histamine receptor inverse agonist. It has subnanomolar affinity for the H3 receptor with Ki of 0.2nM. It possesses stimulant and nootropic effects and analgesic action suggesting a role for H3 receptors in pain processing in the spinal cord. No development was reported about Phase-II clinical trials for Narcolepsy in Europe. Uses: Narcolepsy. Group: Pharmaceutical. CAS No. 720690-73-3. Pack Sizes: 300 mg. Product ID: B0084-459482. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Liraglutide | Liraglutide is the long-acting analogue of glucagon-like peptide-1 (GLP-1) receptor which could protect b-cells from apoptosis under conditions associated with the development of type 1 and type 2 diabetes. Group: Pharmaceutical. CAS No. 204656-20-2. Pack Sizes: 5 mg. Product ID: BAT-010769. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Lixisenatide | Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM). Group: Pharmaceutical. CAS No. 320367-13-3. Pack Sizes: 1 mg. Product ID: BAT-010519. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Mazdutide acetate | Mazdutide acetate is a long-acting glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. Mazdutide acetate stimulates insulin secretion from mouse pancreatic islets, and can be used in studies of obesity and type 2 diabetes (T2D). Group: Pharmaceutical. Pack Sizes: 10 mg. Product ID: B1370-449766. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| MBX-2982 | MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Preclinical data indicate that MBX-2982 is a potent selective orally-active GPR119 agonist that functions through a unique dual mechanism of action. First, it acts directly on the beta cell to increase insulin secretion. In addition, MBX-2982 stimulates release of the incretin GLP-1 from the gut. This dual action is unique and may offer improved glucose homeostasis over existing diabetes therapies, with potential for weight loss and improved islet health. Group: Pharmaceutical. CAS No. 1037792-44-1. Pack Sizes: 20 mg. Product ID: B0084-456604. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| N-acetic acid-1-amino-3-adamantanol | An impurity of Vildagliptin. Vildagliptin is a new dipeptidyl peptidase-4 (DPP-4) inhibitor that is used as an anti-hyperglycemic agent. Vildagliptin could reduce hyperglycemia in type 2 diabetes mellitus via the suppressive effect of inactivation of GLP-1 and GIP by DPP-4. Group: Pharmaceutical. CAS No. 1032564-18-3. Pack Sizes: 500 mg. Product ID: B2694-485169. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Octa(OtBu)-Glu-OtBu | An intermediate in the synthesis of Semaglutide, an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. Group: Pharmaceutical. CAS No. 1188328-39-3. Pack Sizes: 10 mg. Product ID: B2692-383270. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Oxyntomodulin TFA | Oxyntomodulin is a naturally peptide hormone found in the colon, produced by the oxyntic (fundic) cells of the oxyntic (fundic) mucosa. Oxyntomodulin acts as a glucagon-like peptide 1 (GLP-1) receptor agonist. Group: Pharmaceutical. Pack Sizes: 10 mg. Product ID: B1370-427890. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| PX-478 dihydrochloride | PX-478 is an HIF-1alpha inhibitor and an orally active small molecule with potential antineoplastic activity. Although its mechanism of action has yet to be fully elucidated, HIF1-alpha inhibitor PX-478 appears to inhibit hypoxia-inducible factor 1-alpha (HIF1A) expression, which may result in decreased expression of HIF1A downstream target genes important to tumor growth and survival, a reduction in tumor cell proliferation, and the induction of tumor cell apoptosis. The inhibitory effect of this agent is independent of the tumor suppressor genes VHL and p53 and may be related to derangements in glucose uptake and metabolism due to inhibition of glucose transporter-1 (Glut-1). PX-478 has excellent activity against established human tumor xenografts, providing tumor regressions with prolonged growth delays which correlate positively with HIF-1 levels. PX-478 is a highly water soluble molecule, with good i.v., i.p. and p.o. antitumor activity. It is rapidly absorbed following oral and i.p. administration and gives excellent Cmax and AUC via these routes. Group: Pharmaceutical. CAS No. 685898-44-6. Pack Sizes: 100 mg. Product ID: B2693-459441. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Rac-Vildagliptin Impurity F | An impurity of Vildagliptin. Vildagliptin is a new dipeptidyl peptidase-4 (DPP-4) inhibitor that is used as an anti-hyperglycemic agent. Vildagliptin could reduce hyperglycemia in type 2 diabetes mellitus via the suppressive effect of inactivation of GLP-1 and GIP by DPP-4. Group: Pharmaceutical. CAS No. 1789703-36-1. Pack Sizes: 10 mg. Product ID: B2694-485167. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Retatrutide | Retatrutide is a triple glucagon, GIP, and GLP-1 receptor agonist. Retatrutide showed glucose control and weight loss in patients with type 2 diabetes mellitus (T2DM). Uses: retatrutide is a new peptide medication that has showed great promise in drug discovery because of its distinct mode of action and its medicinal uses. the high specificity and affinity of retitrutide for its target receptors is one of the main characteristics that make it an attractive option for drug discovery. this peptide is engineered to bind specifically to specific cell surface receptors. Group: Pharmaceutical. CAS No. 2381089-83-2. Pack Sizes: 10 mg. Product ID: BAT-016112. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Semaglutide | Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. It reduces blood sugar via increasing the production of insulin. On Oct 18, 2017, Novo Nordisk received positive 16-0 vote from FDA Advisory Committee in favor of approval for Semaglutide. Uses: semaglutide, a glucagon-like peptide-1 (glp-1) receptor agonist, has shown promising applications in drug discovery due to its unique pharmacological properties. originally developed for the treatment of type 2 diabetes, semaglutide has recently gained attention for its potential in various therapeutic areas beyond diabetes management. this peptide-based drug has demonstrated efficacy in contro. Group: Pharmaceutical. CAS No. 910463-68-2. Pack Sizes: 5 mg. Product ID: BAT-010191. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Semaglutide D-Leu26 | Semaglutide D-Leu26 is an impurity of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: B1370-449838. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Semaglutide intermediate | Semaglutide intermediate is an intermediate of Semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. Group: Pharmaceutical. CAS No. 1118767-15-9. Pack Sizes: 5 g. Product ID: B2699-009884. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Semaglutide intermediate P29 | An intermediate of Semaglutide, an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. Group: Pharmaceutical. CAS No. 1169630-82-3. Pack Sizes: 10 mg. Product ID: BAT-014339. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu | A 18-carbon fatty acid side chain of semaglutide. The affinity of the semaglutide side chain for albumin was enhanced 5-6 times. Semaglutide is a glucagon-like peptide-1 (GLP-1) analog with significant hypoglycemic efficacy. Group: Pharmaceutical. CAS No. 1118767-16-0. Pack Sizes: 10 mg. Product ID: BAT-008643. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Tirzepatide | Tirzepatide is a dual GIP and GLP-1 receptor agonist and a drug candidate for the treatment of type 2 diabetes. Uses: treating type 2 diabetes is one of the main conditions where tirzepatide shows promise. millions of people worldwide suffer with this chronic illness, which is characterized by poor glucose metabolism and insulin resistance. targeting several receptors, such as the glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) receptors, is part of tirzepatide's distinct. Group: Pharmaceutical. CAS No. 2023788-19-2. Pack Sizes: 5 mg. Product ID: BAT-006246. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Vildagliptin Impurity 3 Trifluoroacetate | An impurity of Vildagliptin. Vildagliptin is a new dipeptidyl peptidase-4 (DPP-4) inhibitor that is used as an anti-hyperglycemic agent. Vildagliptin could reduce hyperglycemia in type 2 diabetes mellitus via the suppressive effect of inactivation of GLP-1 and GIP by DPP-4. Group: Pharmaceutical. CAS No. 565453-41-0. Pack Sizes: 10 mg. Product ID: B2694-485165. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Vildagliptin Impurity A | An impurity of Vildagliptin. Vildagliptin is a new dipeptidyl peptidase-4 (DPP-4) inhibitor that is used as an anti-hyperglycemic agent. Vildagliptin could reduce hyperglycemia in type 2 diabetes mellitus via the suppressive effect of inactivation of GLP-1 and GIP by DPP-4. Group: Pharmaceutical. CAS No. 565453-39-6. Pack Sizes: 250 mg. Product ID: B2694-284718. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Vildagliptin Impurity B | An impurity of Vildagliptin. Vildagliptin is a new dipeptidyl peptidase-4 (DPP-4) inhibitor that is used as an anti-hyperglycemic agent. Vildagliptin could reduce hyperglycemia in type 2 diabetes mellitus via the suppressive effect of inactivation of GLP-1 and GIP by DPP-4. Group: Pharmaceutical. CAS No. 1036959-23-5. Pack Sizes: 500 mg. Product ID: B2694-485168. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Vildagliptin Related Compound A | An impurity of Vildagliptin. Vildagliptin is a new dipeptidyl peptidase-4 (DPP-4) inhibitor that is used as an anti-hyperglycemic agent. Vildagliptin could reduce hyperglycemia in type 2 diabetes mellitus via the suppressive effect of inactivation of GLP-1 and GIP by DPP-4. Group: Pharmaceutical. CAS No. 741657-02-3. Pack Sizes: 10 mg. Product ID: B2694-290136. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
